Sonic Healthcare : 2021 AGM - CEO Presentation

ersonal use only

CEO's AGM Presentation

Dr Colin Goldschmidt

18 November 2021

Headlines

 FY 2021 results
only		Revenue	A$8.8 billion (28% growth)
		EBITDA	A$2.6 billion (81% growth)
		Net profit	A$1.3 billion (149% growth)

 Balance sheet set for growth by acquisition

use

 ersonal

• Gearing at record low level
• Available liquidity ~A$1.5 billion

Progressive dividend strategy maintained

• Final dividend $0.55 per share (franked to 65%)

Strong performance driven by Medical Leadership culture and heroic efforts of 38,000 global staff

Sonic Healthcare Limited l 2021 Annual General Meeting

18 November 2021

COVID-19

 Sonic's COVID testing capability continues to play a crucial role in pandemic control  Sonic contributing essential healthcare services

only		~138 million patients served globally in FY 2021
	~36 million COVID PCR tests performed to date in ~60 Sonic laboratories globally
 COVID vaccinations - Sonic is Australia's largest non-government vaccination provider
 Sonic's pandemic contribution supported by
use		Medical Leadership culture
		Decades of investment in people and infrastructure
 Significant revenue and earnings contribution from COVID testing in FY 2021 and FY 2022 YTD
 Outstanding achievement by Sonic's global staff, working in unrelenting and difficult conditions
ersonal		Sonic Healthcare Limited l 2021 Annual General Meeting	18 November 2021

FY 2021 Revenue Split

SCS/Other

A$410M

use only

NZ

A$29M

Belgium

A$187M 2%

Switzerland

A$579M

7%

UK & Ireland

A$728M

8%

Imaging A$620M 7%

5%

USA

A$2,239M

25%

Revenue in A$ millions

Total Revenue A$8,754 million (including A$3 million interest)

SCS / Other = Sonic Clinical Services (IPN Medical Centres, Sonic HealthPlus, other clinical

ersonal

Australia A$1,977M 23%

Germany A$1,982M 23%

service entities) and other minor operations

Revenue - FY 2021

only	FY 2021 base business revenue*

		Up 6% on FY 2020
		Up 4% on FY 2019 (pre-pandemic)
 Significant contribution from COVID testing
use
* Base business revenue
ersonal
	Total revenue excluding COVID revenue
	 FY 2019 and FY 2020 base business revenues normalised for:
		 Currency exchange rates
		 Acquisitions (Aurora, Epworth Medical Imaging, etc)
		 Disposals (GLP Systems, Ireland)
		 Non-recurring gains

A$ billions

Base business*		COVID

$9.0

$8.0

$7.0

$6.0

$5.0

$4.0 $3.0

$2.0

$1.0

$0.0

FY 2019

FY 2020

FY 2021